Oncogenic Variant RON160 Expression in Breast Cancer and its Potential as a Therapeutic Target by Small Molecule Tyrosine Kinase Inhibitor

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|13|6|686-697

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.13, Iss.6, 2013-07, pp. : 686-697

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Macrophage Stimulating Protein/Ron Pathway as a Potential Therapeutic Target to Impede Multiple Mechanisms Involved in Breast Cancer Progression

By  

Current Drug Targets, Vol. 11, Iss. 9, 2010-09 ,pp. : 1157-1168

Bentham Science Publishers

Access to resources Recommend Favorite

Mechanisms of Clinical Resistance to Small Molecule Tyrosine Kinase Inhibitors Targeting Oncogenic Tyrosine Kinases

By Heiko van der Kuip  

American Journal of PharmacoGenomics, Vol. 5, Iss. 2, 2005-01 ,pp. : 101-112

Adis International

Access to resources Recommend Favorite

Oncogenic Signaling Pathways Activated by RON Receptor Tyrosine Kinase

By  

Current Cancer Drug Targets, Vol. 3, Iss. 1, 2003-02 ,pp. : 31-40

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer

By  

Current Cancer Drug Targets, Vol. 18, Iss. 4, 2018-04 ,pp. : 306-327

Bentham Science Publishers

Access to resources Recommend Favorite

Small Molecule Tyrosine Kinase Inhibitors: The New Dawn for Cancer Therapy

By  

Letters in Drug Design & Discovery, Vol. 9, Iss. 1, 2012-01 ,pp. : 84-125

Bentham Science Publishers

Access to resources Recommend Favorite